AVIR
Price
$3.37
Change
+$0.04 (+1.20%)
Updated
Jan 17 closing price
Capitalization
284.64M
44 days until earnings call
RYTM
Price
$54.54
Change
-$0.12 (-0.22%)
Updated
Jan 17 closing price
Capitalization
3.35B
44 days until earnings call
Ad is loading...

AVIR vs RYTM

Header iconAVIR vs RYTM Comparison
Open Charts AVIR vs RYTMBanner chart's image
Atea Pharmaceuticals
Price$3.37
Change+$0.04 (+1.20%)
Volume$337.67K
Capitalization284.64M
Rhythm Pharmaceuticals
Price$54.54
Change-$0.12 (-0.22%)
Volume$593.18K
Capitalization3.35B
AVIR vs RYTM Comparison Chart
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. RYTM commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Hold and RYTM is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (AVIR: $3.37 vs. RYTM: $54.54)
Brand notoriety: AVIR and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 80% vs. RYTM: 108%
Market capitalization -- AVIR: $284.64M vs. RYTM: $3.35B
AVIR [@Biotechnology] is valued at $284.64M. RYTM’s [@Biotechnology] market capitalization is $3.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 0 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 0 green, 5 red.
According to our system of comparison, RYTM is a better buy in the long-term than AVIR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 3 TA indicator(s) are bullish while RYTM’s TA Score has 4 bullish TA indicator(s).

  • AVIR’s TA Score: 3 bullish, 3 bearish.
  • RYTM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AVIR is a better buy in the short-term than RYTM.

Price Growth

AVIR (@Biotechnology) experienced а +3.06% price change this week, while RYTM (@Biotechnology) price change was -2.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

AVIR is expected to report earnings on May 07, 2025.

RYTM is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($3.35B) has a higher market cap than AVIR($285M). AVIR YTD gains are higher at: 0.597 vs. RYTM (-2.572). AVIR has higher annual earnings (EBITDA): -200.08M vs. RYTM (-237.01M). AVIR has more cash in the bank: 483M vs. RYTM (298M). AVIR has less debt than RYTM: AVIR (1.84M) vs RYTM (4.03M). RYTM has higher revenues than AVIR: RYTM (113M) vs AVIR (0).
AVIRRYTMAVIR / RYTM
Capitalization285M3.35B9%
EBITDA-200.08M-237.01M84%
Gain YTD0.597-2.572-23%
P/E RatioN/AN/A-
Revenue0113M-
Total Cash483M298M162%
Total Debt1.84M4.03M46%
FUNDAMENTALS RATINGS
AVIR vs RYTM: Fundamental Ratings
AVIR
RYTM
OUTLOOK RATING
1..100
8777
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
98
Overvalued
PROFIT vs RISK RATING
1..100
9837
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
5645
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVIR's Valuation (43) in the Biotechnology industry is somewhat better than the same rating for RYTM (98). This means that AVIR’s stock grew somewhat faster than RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (37) in the Biotechnology industry is somewhat better than the same rating for AVIR (98). This means that RYTM’s stock grew somewhat faster than AVIR’s over the last 12 months.

AVIR's SMR Rating (96) in the Biotechnology industry is in the same range as RYTM (100). This means that AVIR’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Price Growth Rating (45) in the Biotechnology industry is in the same range as AVIR (56). This means that RYTM’s stock grew similarly to AVIR’s over the last 12 months.

AVIR's P/E Growth Rating (95) in the Biotechnology industry is in the same range as RYTM (100). This means that AVIR’s stock grew similarly to RYTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRRYTM
RSI
ODDS (%)
Bearish Trend 12 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
89%
Momentum
ODDS (%)
N/A
Bullish Trend 12 days ago
86%
MACD
ODDS (%)
N/A
Bullish Trend 12 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
84%
Bullish Trend 12 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
75%
Bullish Trend 12 days ago
77%
Advances
ODDS (%)
Bullish Trend 17 days ago
77%
Bullish Trend about 1 month ago
81%
Declines
ODDS (%)
Bearish Trend 12 days ago
80%
Bearish Trend 14 days ago
79%
BollingerBands
ODDS (%)
N/A
Bearish Trend 12 days ago
84%
Aroon
ODDS (%)
N/A
Bearish Trend 12 days ago
85%
View a ticker or compare two or three
Ad is loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEEFX83.370.86
+1.04%
American Funds Fundamental Invs 529-F-3
MFLLX16.580.16
+0.97%
Morgan Stanley Inst Inception R6
LGCFX16.980.14
+0.83%
Lord Abbett Global Equity F
PZHEX12.640.08
+0.64%
T. Rowe Price Hedged Equity Z
NRIIX21.270.02
+0.09%
Nuveen Real Asset Income I

AVIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with HEPA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then HEPA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
+1.20%
HEPA - AVIR
47%
Loosely correlated
+4.22%
AXON - AVIR
46%
Loosely correlated
+1.37%
RCKT - AVIR
45%
Loosely correlated
+0.98%
CDXS - AVIR
45%
Loosely correlated
+1.63%
MGTX - AVIR
44%
Loosely correlated
+5.56%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with RCKT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
-0.22%
RCKT - RYTM
46%
Loosely correlated
+0.98%
ERAS - RYTM
44%
Loosely correlated
-0.54%
KYMR - RYTM
42%
Loosely correlated
+0.79%
AVIR - RYTM
42%
Loosely correlated
+1.20%
RVMD - RYTM
41%
Loosely correlated
+0.98%
More